Deacetylravidomycin
(Synonyms: 去乙酰基拉维霉素) 目录号 : GC43390
A microbial metabolite with light-dependent antibiotic and anticancer activities
Cas No.:88580-27-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Deacetylravidomycin is a microbial metabolite that has been found in Streptomyces and has light-dependent antibiotic and anticancer activities. It is active against Gram-positive bacteria, including B. subtilis, S. aureus, S. epidermidis, and E. faecalis (MICs = 0.78-1.56 and <0.006-0.049 μg/ml in the absence and presence of fluorescent light, respectively). Deacetylravidomycin also reduces colony formation by human colon cancer cells in a clonogenic assay in a light-dependent manner.
| Cas No. | 88580-27-2 | SDF | |
| 别名 | 去乙酰基拉维霉素 | ||
| Canonical SMILES | CN(C)[C@@H]1[C@@H](O)[C@H](C2=CC=C(O)C3=C(OC)C=C(C4=C(OC)C=C(C=C)C=C4C(O5)=O)C5=C32)O[C@H](C)[C@@H]1O | ||
| 分子式 | C29H31NO8 | 分子量 | 521.6 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9172 mL | 9.5859 mL | 19.1718 mL |
| 5 mM | 0.3834 mL | 1.9172 mL | 3.8344 mL |
| 10 mM | 0.1917 mL | 0.9586 mL | 1.9172 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Deacetylravidomycin M, a new inhibitor of IL-4 signal transduction, produced by Streptomyces sp. WK-6326. II. Structure elucidation
J Antibiot (Tokyo) 2001 Jul;54(7):562-6.PMID:11560374DOI:10.7164/antibiotics.54.562.
The structure of Deacetylravidomycin M, an inhibitor of interleukin-4 signal transduction, was elucidated to be 6H-benzo[d]naphtho[1,2-b]pyran-6-one, 4-[3,6-dideoxy-3-(dimethylamino)-alpha-altropyranosyl]-1-hydroxy-10,12-dimethoxy-8-methyl- by spectroscopic studies including NMR measurements.
Deacetylravidomycin M, a new inhibitor of IL-4 signal transduction, produced by Streptomyces sp. WK-6326. I. Taxonomy, fermentation, isolation and biological activities
J Antibiot (Tokyo) 2001 Jul;54(7):554-61.PMID:11560373DOI:10.7164/antibiotics.54.554.
Streptomyces sp. WK-6326, a soil isolate, was found to produce an inhibitor of interleukin (IL)-4 signal transduction. Two structurally related compounds, a novel one designated Deacetylravidomycin M and the known Deacetylravidomycin, were isolated from the culture broth by solvent extraction, silica gel column chromatography and HPLC. Deacetylravidomycin M inhibited IL-4-induced CD23 expression in U937 cells without any cytotoxic effect, whereas Deacetylravidomycin showed no inhibitory activity.
Deacetylravidomycin N-oxide, a new antibiotic. Taxonomy and fermentation of the producing organism and isolation, structure and biological properties of the antibiotic
J Antibiot (Tokyo) 1989 Mar;42(3):347-56.PMID:2708127DOI:10.7164/antibiotics.42.347.
Streptomyces ravidus S50905 was found to produce a new antibiotic, Deacetylravidomycin N-oxide, together with ravidomycin and Deacetylravidomycin in a culture medium containing sodium anthraquinone-beta-sulfonate. The structure of this new compound was determined from NMR and mass spectrometric data, and further confirmed by chemical synthesis from Deacetylravidomycin. Deacetylravidomycin N-oxide was antitumor active against P388 leukemia and Meth A fibrosarcoma in a wide range of doses, and considerably less toxic than Deacetylravidomycin. Its antibacterial activity was less potent than Deacetylravidomycin. Ravidomycin N-oxide was also synthesized from ravidomycin and its biological properties were tested.